This is not the most recent version of the article. View current version (31 MAY 2013)

Intervention Review

Mitoxantrone for multiple sclerosis

  1. Filippo Martinelli Boneschi1,*,
  2. Marco Rovaris2,
  3. Ruggero Capra3,
  4. Giancarlo Comi4

Editorial Group: Cochrane Multiple Sclerosis Group

Published Online: 19 OCT 2005

Assessed as up-to-date: 23 AUG 2005

DOI: 10.1002/14651858.CD002127.pub2

How to Cite

Martinelli Boneschi F, Rovaris M, Capra R, Comi G. Mitoxantrone for multiple sclerosis. Cochrane Database of Systematic Reviews 2005, Issue 4. Art. No.: CD002127. DOI: 10.1002/14651858.CD002127.pub2.

Author Information

  1. 1

    INSPE - San Raffaele Scientific Institute, Department of Neurology, Milano, Italy

  2. 2

    San Raffaele Institute, Neuroimaging Research Unit, Milano, Italy

  3. 3

    Spedali Civili, Brescia, Italy

  4. 4

    San Raffaele Hospital, Department of Neurology, Milano, Italy

*Filippo Martinelli Boneschi, Department of Neurology, INSPE - San Raffaele Scientific Institute, Via Olgettina, 48, Milano, 20131, Italy.

Publication History

  1. Publication Status: Edited (no change to conclusions)
  2. Published Online: 19 OCT 2005


This is not the most recent version of the article. View current version (31 MAY 2013)

Cited in:


This article has been cited by:

  1. 1
    Alan M. Palmer, New and emerging immune-targeted drugs for the treatment of multiple sclerosis, British Journal of Clinical Pharmacology, 2014, 78, 1
  2. 2
    Paul W. O’Connor, Jiwon Oh, Multiple Sclerosis and Related Disorders, 2014,


  3. 3
    Paolo Zamboni, Antonio Bertolotto, Paolo Boldrini, Patrizia Cenni, Roberto D’Alessandro, Roberto D’Amico, Massimo Del Sette, Roberto Galeotti, Stefania Galimberti, Alessandro Liberati, Luca Massacesi, Donato Papini, Fabrizio Salvi, Silvana Simi, Andrea Stella, Luigi Tesio, Maria Grazia Valsecchi, Graziella Filippini, Efficacy and safety of venous angioplasty of the extracranial veins for multiple sclerosis. Brave dreams study (brain venous drainage exploited against multiple sclerosis): study protocol for a randomized controlled trial, Trials, 2012, 13, 1, 183


  4. 4
    Babak Jalilian, Halldór Einarsson, Thomas Vorup-Jensen, Glatiramer Acetate in Treatment of Multiple Sclerosis: A Toolbox of Random Co-Polymers for Targeting Inflammatory Mechanisms of both the Innate and Adaptive Immune System?, International Journal of Molecular Sciences, 2012, 13, 12, 14579


  5. 5
    Annette Wundes, George H. Kraft, James D. Bowen, Ted A. Gooley, Richard A. Nash, Mitoxantrone for worsening multiple sclerosis: Tolerability, toxicity, adherence and efficacy in the clinical setting, Clinical Neurology and Neurosurgery, 2010, 112, 10, 876


  6. 6
    Alfonso Ciccone, Sandro Beretta, Fabio Brusaferri, Ian Galea, Alessandra Protti, Chiara Spreafico, Corticosteroids for the long-term treatment in multiple sclerosis, The Cochrane Library,
  7. 7
    Graziella Filippini, Cinzia Del Giovane, Laura Vacchi, Roberto D'Amico, Carlo Di Pietrantonj, Deirdre Beecher, Georgia Salanti, Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis, The Cochrane Library,
  8. 8
    Orla Gray, Gavin V McDonnell, Raeburn B Forbes, Intravenous immunoglobulins for multiple sclerosis, The Cochrane Library,